论文部分内容阅读
用国产重组酵母和重组ＣＨＯ乙型肝炎疫苗对７５名ＨＢｓＡｇ／ＨＢｅＡｇ阳性母亲所生的婴儿进行免疫。结果在免疫后２年，基因重组乙肝疫苗的抗－ＨＢｓ阳性率仍保持较高水平，重组酵母乙肝疫苗组的抗－ＨＢｓ阳性率（１００．０％）则显著高于重组ＣＨＯ乙肝疫苗组（９１．４％）和血源性乙肝疫苗＋ＨＢＩＧ组（８０．０％）。各组的抗－ＨＢｓ滴度（Ｓ／Ｎ值）在免疫后９个月时形成高峰，１２个月时开始下降，在２４个月时，５μｇ重组酵母乙肝疫苗组、２０μｇ重组ＣＨＯ乙肝疫苗组的仍有较高抗体滴度（分别为８４．７和７０．９），其下降的速度（分别为１６．７％，２２．２％）低于３０μｇ血源性乙肝疫苗＋ＨＢＩＧ组（３４．２％）。说明国产基因乙肝疫苗具有良好的免疫原性和高度的保护效果
Seventy-five infants born to HBsAg / HBeAg-positive mothers were immunized with domestic recombinant yeast and recombinant CHO hepatitis B vaccine. Results The positive rate of anti-HBs in recombinant hepatitis B vaccine remained high at 2 years after immunization. The positive rate of anti-HBs (100.0%) in recombinant yeast hepatitis B vaccine group was significantly higher than that in recombinant CHO hepatitis B vaccine group 91.4%) and blood-borne hepatitis B vaccine + HBIG group (80.0%). The anti-HBs titer (S / N) in each group peaked at 9 months after immunization and began to decline at 12 months. At 24 months, 5μg recombinant yeast hepatitis B vaccine group, 20μg recombinant CHO hepatitis B vaccine group (84.7 and 70.9, respectively) still had lower antibody titers (16.7% and 22.2%, respectively) than the blood-borne HB vaccine + HBIG group (34. 2%). This shows that domestic gene hepatitis B vaccine has good immunogenicity and high degree of protection